Synairgen Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Synairgen ha un patrimonio netto totale di £9.6M e un debito totale di £0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente £10.6M e £1.1M.

Informazioni chiave

Rapporto debito/patrimonio netto

UK£0

Debito

Indice di copertura degli interessi	n/a
Contanti	UK£8.59m
Patrimonio netto	UK£9.56m
Totale passività	UK£1.08m
Totale attività	UK£10.64m

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Dec 09

Recent updates

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Dec 09

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Aug 24

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Apr 29

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Dec 27

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Sep 13

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

May 31

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Feb 06

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Oct 21

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Mar 29

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

Dec 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( £10.5M ) di SNG superano le sue passività a breve termine ( £1.1M ).

Passività a lungo termine: SNG non ha passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: SNG è esente da debiti.

Riduzione del debito: SNG non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: SNG ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: SNG ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 12.3 % ogni anno

Synairgen Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Recent updates

New major risk - Financial position

Synairgen plc, Annual General Meeting, Oct 10, 2024

New minor risk - Financial data availability

Synairgen plc Announces Stepping Down of Phillip Monk from the Board, Effective December 31, 2024

New major risk - Market cap size

New major risk - Share price stability

New minor risk - Financial data availability

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

New major risk - Share price stability

Synairgen plc Announces Executive Changes

Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc, Annual General Meeting, Jun 29, 2023

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research

Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee

Price target decreased to UK£2.20

No independent directors

Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health (Nih)/ Aids Clinical Trials Group (Actg)-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19

Synairgen plc Announces Changes to Its Board

Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients

Synairgen plc Announces Collaboration on Universal Trial

Synairgen plc, Annual General Meeting, Jun 30, 2022

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Less than half of directors are independent

Synairgen plc to Report Fiscal Year 2021 Results on May 25, 2022

Synairgen plc Provides Update on SNG001 in the ACTIV-2 Phase 3 Trial for COVID-19 and on SNG001 Activity Against Delta and Omicron Variants

Price target decreased to UK£2.20

Synairgen plc Announces Topline Results from Phase 3 SPRINTER trial of SNG001

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Synairgen plc Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen plc Announces Results of in Vitro Studies

Synairgen Announces Data from Home Cohort of SG016 Phase II Trial of Inhaled Interferon Beta in COVID-19 Patients and Encouraging Combined Data for Whole SG016 Trial

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Synairgen Announces Dosing Has Commenced with Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients

New 90-day high: UK£1.90

New 90-day high: UK£1.88

Synairgen Announces Inclusion of Its Inhaled Interferon Beta Treatment in US NIH ACTIV-2 trial in COVID-19 outpatients

Synairgen plc Announces Completion of Recruitment into Its Phase Ii Home-Based Covid-19 Study of Inhaled Interferon Beta

Synairgen Announces Commencement of Dosing in Its International Phase III Study of Inhaled Interferon Beta in Hospitalised COVID-19 Patients

Synairgen plc Provides COVID-19 Clinical Programme Update

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

New 90-day low: UK£0.77

Clinigen Group plc Signs Managed Access Program Agreement with Synairgen plc

New 90-day high - UK£2.32

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane